<DOC>
	<DOC>NCT00090766</DOC>
	<brief_summary>This study will assess the safety and pharmacokinetics of Valcyte syrup in pediatric solid organ transplant recipients. The anticipated time on study treatment is 3-12 months and the target sample size is less than 100 individuals.</brief_summary>
	<brief_title>A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>patients between 3 months and 16 years of age; first solid organ transplant (eg, kidney, liver, heart); able to tolerate oral medication; females of childbearing potential must agree to utilize an effective method of contraception throughout the study and for 90 days following discontinuation of study drug; patients at risk of developing CMV disease (all transplant recipients other than those who are DR for CMV). patients who have previously participated in this study; patients who are participating in another clinical trial (except with the approval of the Sponsor); severe, uncontrolled diarrhea (more than 5 watery stools per day); pregnant or lactating females.</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>